Levetiracetam was approved for medical use in the United States in 1999 and is available as a generic medication. Levetiracetam is a novel anticonvulsant agent used as an adjunct medication to manage partial-onset, myoclonic, and generalized tonic-clonic seizures in patients with epilepsy.
The United States Pharmacopeia (USP) provides monographs for identification and impurity testing of the drug substance. This application brief describes use of the LC 300 liquid chromatography system and SimplicityChrom chromatography data system (CDS) for the analysis of Levetiracetam as per the USP monograph.